{"id":"ad3831cc-2596-5016-be16-8401fd4adb18","stable_key":"182336c6-ed36-5ec6-8a09-25c31096262e:dim-i3c-human-1a2","predicate":"increases_measured_activity_of","statement":"I3C increased caffeine-probed CYP1A2 activity in 94% of participants in the phase I study.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"7a6f312e-24c0-516c-a412-14fb8f4bc9e1","mechanism_event_label":"There is human evidence for the precursor, but it must not be silently relabeled as a DIM trial.","subject":{"id":"0e7ccfc7-b9a1-53e0-88f4-a061579ad94d","slug":"indole-3-carbinol","display_name":"Indole-3-carbinol / I3C","entity_type_key":"small_molecule"},"object":{"id":"9b15c13c-a369-5d10-a76a-525e8b19221d","slug":"cyp1a2","display_name":"Human cytochrome P450 1A2","entity_type_key":"protein"},"evidence_count":1,"mechanism_event":{"id":"7a6f312e-24c0-516c-a412-14fb8f4bc9e1","stable_key":"182336c6-ed36-5ec6-8a09-25c31096262e:dim-i3c-human-1a2-event","event_type":"observed_intervention","label":"There is human evidence for the precursor, but it must not be silently relabeled as a DIM trial.","description":"I3C increased caffeine-probed CYP1A2 activity in 94% of participants in the phase I study.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"ef028472-7c33-583d-b52e-40676004d370","slug":"caffeine","display_name":"Caffeine","entity_type_key":"small_molecule"},"role":"probe","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"0e7ccfc7-b9a1-53e0-88f4-a061579ad94d","slug":"indole-3-carbinol","display_name":"Indole-3-carbinol / I3C","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"9b15c13c-a369-5d10-a76a-525e8b19221d","slug":"cyp1a2","display_name":"Human cytochrome P450 1A2","entity_type_key":"protein"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/dim-research/16103443.abstract.txt\", \"locator\": \"Primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"ece0ac1a0c31053cdc1ec3eefbf9c78887018e0eddf2db36c3a1a07c998e15c4\", \"start_char\": 0, \"end_char\": 1706, \"text_sha256\": \"ece0ac1a0c31053cdc1ec3eefbf9c78887018e0eddf2db36c3a1a07c998e15c4\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Phase I placebo run-in and dose escalation","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"I3C 400 mg/day then 800 mg/day for four weeks each","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"The administered compound was I3C, not DIM. Multiple acid-condensation products and nonrandomized sequential periods prevent assigning the observed fold change specifically to DIM.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Diindolylmethane (DIM) research collection; topical membership is not evidence of a direct dietary effect.","comparator":null,"unit":null,"notes":"","entity":{"slug":"dim","display_name":"3,3'-Diindolylmethane / DIM","entity_type_key":"small_molecule"}},{"dimension":"organism","value_text":"17 women at elevated breast-cancer risk","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"There is human evidence for the precursor, but it must not be silently relabeled as a DIM trial.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[dim-p16103443] A phase I study of indole-3-carbinol in women: tolerability and effects. (2005). https://pubmed.ncbi.nlm.nih.gov/16103443/ DOI: 10.1158/1055-9965.epi-05-0121","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Caffeine CYP1A2 phenotype and estrogen metabolites","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"646d6e11-a9cd-5400-b700-3aefe6febe32","evidence_kind":"source_excerpt","locator":"Lines 1026-1037","start_line":1026,"end_line":1037,"excerpt":"### dim-i3c-human-1a2\nI3C increased caffeine-probed CYP1A2 activity in 94% of participants in the phase I study.\nCondition category: normal\nnutrient_topic: Diindolylmethane (DIM) research collection; topical membership is not evidence of a direct dietary effect.\nplain_language: There is human evidence for the precursor, but it must not be silently relabeled as a DIM trial.\norganism: 17 women at elevated breast-cancer risk\ntissue_or_cell_type: Caffeine CYP1A2 phenotype and estrogen metabolites\nexperimental_model: Phase I placebo run-in and dose escalation\nlimitations: The administered compound was I3C, not DIM. Multiple acid-condensation products and nonrandomized sequential periods prevent assigning the observed fold change specifically to DIM.\nexposure: I3C 400 mg/day then 800 mg/day for four weeks each\nevidence_span: {\"source_cache\": \"artifacts/dim-research/16103443.abstract.txt\", \"locator\": \"Primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"ece0ac1a0c31053cdc1ec3eefbf9c78887018e0eddf2db36c3a1a07c998e15c4\", \"start_char\": 0, \"end_char\": 1706, \"text_sha256\": \"ece0ac1a0c31053cdc1ec3eefbf9c78887018e0eddf2db36c3a1a07c998e15c4\"}\n[dim-p16103443] A phase I study of indole-3-carbinol in women: tolerability and effects. (2005). https://pubmed.ncbi.nlm.nih.gov/16103443/ DOI: 10.1158/1055-9965.epi-05-0121","model_system":"Phase I placebo run-in and dose escalation","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [dim-p16103443] A phase I study of indole-3-carbinol in women: tolerability and effects. (2005). https://pubmed.ncbi.nlm.nih.gov/16103443/ DOI: 10.1158/1055-9965.epi-05-0121","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"b6d70682-97f9-5893-a03c-f9f88836033c","stable_key":"import-182336c6-ed36-5ec6-8a09-25c31096262e","title":"Diindolylmethane (DIM): formation, receptor signaling, metabolism and drug interactions (2026-09-17)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"31e14060de904976d2f5d439f2bc9c8a99a72d34626c562c78429025e050d404","revision_id":"611094c1-a9cf-5b9b-b255-ac70b571696a","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}